In Israel, infections fall sharply after a shot of the vaccine

JERUSALEM – Israel, a leader in vaccinating its population against the corona virus, has some encouraging news: Preliminary results show a significant drop in infection after just one shot of the two-dose vaccine. And better results than expected after both doses.

Public health experts have warned that the data based on Pfizer biotech vaccines are preliminary and have not received medical treatment. Nevertheless, Dr. Anat Aka Zohar, vice president of Macbeth Health Services, one of the Israeli health care organizations that released the data, called it “very encouraging.”

In the first preliminary report, Clayt, Israel’s largest health fund, compared 200,000 people aged 60 and over who received the first dose of the vaccine from a similar group of 200,000 people who have yet to be vaccinated. The vaccine was not given. He said he was partially vaccinated 14 to 18 days after his shots The chance of infection is 33% lower.

Around the same time, McBee’s research team said it had seen an even greater reduction in infections after just one dose: about 60 percent after the first shot, 13 to 21 days later, before receiving it. In 430,000 people.

Maccabee did not specify any age group or compare the data with any vaccination cohort.

On Monday, the Israeli Ministry of Health and McCabe released new data on people who received both doses of the vaccine, which showed extremely high rates of effectiveness.

The ministry found that of the 428,000 Israelis who received their second dose, only 63 or 0.014% received the virus a week later. Similarly, Maccabee’s data show that more than a week after receiving the second dose, only 20 out of 8,128,600 people, about 0.0 0.01 percent, became infected.

In clinical trials, the pacer vaccine has been shown to be 95% effective in preventing coronavirus infections in people without evidence of previous infection after two doses. Israeli results, if they are maintained, suggest that the utility may be even higher, although harsh comparisons with non-competitors have not yet been published.

“This is very encouraging data,” said Dr. Zohar. “We will closely monitor these patients to see if they are suffering from mild symptoms and do not have complications as a result of the virus.” ۔ “

Both Clayt and Maccabee warned that their search was preliminary and said they would soon conduct more in-depth statistical analysis in peer-reviewed scientific publications.

Israel, where more than 40 percent of the population has already received the first dose of the vaccine, has become an international test case for the effectiveness of the vaccine.

With its small population, highly digitized universal healthcare system, and rapid, military-assisted vaccine rollout, Israel’s real-world data provides a useful supplement for clinical trials for researchers, pharmaceutical companies and policy makers. ۔

Israel entered into an agreement with Pfizer in which the drug company ensured the supply of vaccines to the country quickly and permanently in exchange for the data. The Ministry of Health has released a red version of the agreement.

Despite its vaccination race, Israel is suffering from a devastating third wave of the corona virus. After weeks of increasing infections and deaths, the government imposed a severe national lockdown this month.

Israel was to stop most of its air travel, starting at midnight on Monday, in the country and abroad in an effort to stem the spread of the virus, which could jeopardize the country’s immunization campaign. Two vaccine makers said Monday that their vaccines are slightly less effective against one of the new strains.

Although such actual data obtained from Israel is useful, it is subject to variables that may result in loss of results and what clinical trials try to calculate.

Although the exact order of vaccine recipients may vary by state, most medical workers and residents of long-term care facilities will take precedence. If you want to understand how this decision is being made, this article will help.

Life will return to normal only when society as a whole is well protected against the coronavirus. Once countries allow a vaccine, they will already be able to get a small percentage of their citizens vaccinated in the first few months. The majority of unsigned patients will still be at risk for infection. Growing coronavirus vaccines are showing strong protection against getting sick. But it is also possible that people find out that they spread the virus without being infected because they only get mild symptoms or nothing at all. Scientists do not yet know whether vaccines also stop the transmission of coronavirus. Therefore, for a while, even people with immunizations will need to wear masks, avoid indoor crowds, and so on. Once enough people have been vaccinated against polio, it will be very difficult for people with the coronavirus to be infected. Depending on how quickly we as a society achieve this goal, life will begin to reach something normal by the fall of 2021.

Yes, but not forever. Two vaccines, possibly administered this month, will clearly prevent people from getting sick with code 19. But the clinical trials that presented these results were not designed to determine whether vaccinated people can spread the corona virus without developing symptoms. That remains a possibility. We know that people who are naturally infected with the coronavirus can spread it when they are not experiencing a cough or other symptoms. Researchers will study this question as soon as the vaccine is launched. In the meantime, even vaccinated people will need to think of themselves as a potential spread.

Pfizer and biotech vaccines are given as a shot in the arm like other common vaccines. The injection will not be different from what you have taken before. Tens of thousands of people have already received the vaccine and none of them are reported to have serious health problems. But some of them have experienced minor discomfort, including pain and flu-like symptoms that usually last a day. It is possible that after the second shot, people may need to plan a day off from work or school. Although these experiments are not pleasant, they are a good sign: they are the result of your own immune system exposure to the vaccine and a strong mounting reaction that will provide lasting immunity.

no. Modern and Pfizer vaccines use genetic molecules to improve the immune system. The molecule, known as mRNA, is eventually destroyed by the body. The mRNA is packaged in an oil bubble that can fuse a cell, causing the molecule to slip. The cell uses mRNA to make proteins from the corona virus, which can stimulate the immune system. At any given moment, each of our cells could contain millions of mRNA molecules, which they themselves produce to make proteins. Once they become proteins, our cells explode mRNA with special enzymes. The mRNA molecules produced by our cells can survive in just a few minutes. MRNAs in vaccines are engineered to make cell enzymes slightly more tolerant, so that the cells can make extra virus proteins and speed up the immune response. But mRNA can only survive for a few days before it is destroyed.

Early Israeli numbers are based on the first people to receive the vaccine. Experts say such people are more likely to be anxious or aware of the virus, so be more careful about social distance and wearing a niqab. They may also be different from people who were not in a hurry to shoot because of their location and socio-economic status.

Also, experts say, the disease changes over time. Professor Run Belisher, Kleit’s chief innovation officer and a leading Israeli affairs expert, said the two-week-old figures could be evidence of a different era or “about a million vaccines in Israeli terms”.

Maccabee said he would release more data weekly. “The key message, is that even the first dose of the vaccine is effective,” said Maccabee, “reducing the patient’s risk of hospitalization by tens of percent.” “

Experts warn that the risk of releasing raw data is that it could be misinterpreted.

When Clayte first announced his initial numbers two weeks ago, many people expected to hear about the 33% reduction, not 95%, and came to the wrong conclusion that the Pfizer shot didn’t work.

There was an uproar in the UK, where authorities delayed the delivery of the second dose by up to 12 weeks, 21 days apart, on which Pfizer based his case.

Professor Belisher considered the results good news and was amazed at how they were interpreted.

“We have been reassured to let everyone know that what we are seeing is what we are seeing after 14 days,” he said. “I don’t know how it turned into the message ‘Oh my God, it doesn’t work.'”

Professor Baliker, who is also chairman of the team of experts advising the Israeli government on its Code 19 response, expressed hope that the government’s one-sided decision on the third lockdown would yield positive results.

“The code has made us all amateur scientists,” said Talia Maron Schott, a professor at Central Israel and a medical decision-maker at Ono Academic College in central Israel. “We’re all looking at data, but most people are not scientists.”

Israel, which began vaccinating people on December 20, gave the first shot to more than 2.6 million Israelis and both shots to more than a million people.

After starting at high risk for people 60 years of age or older, healthcare workers and others, Israel now has a high school age for people over 40 and 16 to 18 years old. Vaccinating students to allow them to return to school. The Army is assisting in this effort and is assisting 700 Army Reserve Medicine Vaccination Centers.

Professor Jonathan Halvey, president of the Sherzad Medical Center in Jerusalem, did not study the search for HMOs, but said that two weeks after the first dose was prepared, he saw a decrease in severe cases.

“I know many people who were affected by the vaccine, but they got it lightly,” he said.

Still, Israel is under a national lockdown and authorities are concerned about the emergence of new, highly contagious variants. It remains to be seen how effective vaccines are against new strains.

Despite the initial success of the vaccine, the virus is wreaking havoc in Israel. Professor Holloway said his hospital’s coveted wards are still overcrowded and he expects it to take another two to three weeks to see a reduction.

The virus has killed more than 1,000 Israelis this month, a quarter of the total.

Health officials and experts have described the recent rise in infections as the first variable in the rapid spread in the UK.

Leave a Reply

Your email address will not be published. Required fields are marked *